NMD Agents Reduce TDP-43 Toxicity in ALS Neuronal Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective treatment for amyotrophic lateral sclerosis (ALS), with current therapies only extending the lifespan of patients by a few months.
Innovation Solution
The use of agents involved in nonsense-mediated mRNA decay (NMD), such as UPF1, UPF2, UPF3, SMG1, SMG5, SMG6, or SMG7 polypeptides, to reduce toxicity associated with TDP-43 or FUS/TLS proteins in neuronal cells, thereby treating or preventing ALS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current ALS treatments (e.g., riluzole) are used, then patient lifespan is extended by a few months, but the treatment effectiveness remains insufficient and the disease continues to progress relentlessly
Solution Approach 1:
The patent introduces NMD pathway components (UPF1, UPF2, UPF3, SMG1, SMG5, SMG6, or SMG7 polypeptides) as intermediary molecules that mediate between the toxic TDP-43/FUS/TLS proteins and the neuronal cell machinery. These NMD agents act as protective intermediaries that recognize and facilitate the degradation of toxic RNA transcripts, thereby reducing protein toxicity without directly confronting the underlying disease mechanism
Solution Approach 2:
The patent converts the harmful accumulation of TDP-43/FUS/TLS toxic proteins into a beneficial therapeutic opportunity by activating the NMD pathway. Instead of trying to prevent protein accumulation directly, the treatment exploits the cell's existing NMD quality control mechanism to recognize and eliminate toxic RNA transcripts, thereby converting a harmful condition into a therapeutic target
2Ease of manufacture
If no treatment is administered, then the disease progresses naturally with death occurring 3-5 years after onset, but there is complete absence of therapeutic intervention to slow progression
Solution Approach 1:
The patent enables the neuronal cells to self-protect against TDP-43/FUS/TLS toxicity by enhancing their endogenous NMD pathway. The NMD agents administered stimulate the cell's own quality control machinery to recognize and degrade toxic RNA transcripts, allowing the cells to fight the disease using their intrinsic defense mechanisms rather than relying on external protective structures
3Object-affected harmful factors
If NMD agents (UPF1, UPF2, UPF3, SMG1, SMG5, SMG6, or SMG7 polypeptides) are administered to reduce TDP-43 or FUS/TLS toxicity, then neuronal cell protection is achieved, but the complexity of identifying and administering the correct agent increases
Solution Approach 1:
The patent identifies multiple NMD pathway components (UPF1, UPF2, UPF3, SMG1, SMG5, SMG6, or SMG7 polypeptides) that can all serve the same protective function against TDP-43/FUS/TLS toxicity. This universality provides flexibility in treatment selection, as any of these agents can potentially achieve the desired therapeutic effect, simplifying the overall treatment strategy despite the multiple options available
Data Source
AI summary
Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.